Loading clinical trials...
Loading clinical trials...
An Open-label, Non-randomized Study on Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of LNP023 in Two Patient Populations With C3 Glomerulopathy
Conditions
Interventions
LNP023
Locations
9
United States
Novartis Investigative Site
Iowa City, Iowa, United States
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Ranica, BG, Italy
Novartis Investigative Site
Barcelona, Catalonia, Spain
Start Date
February 20, 2019
Primary Completion Date
April 23, 2021
Completion Date
April 23, 2021
Last Updated
January 30, 2024
NCT00977977
NCT05996731
NCT06858319
NCT06047171
NCT01802034
NCT05510323
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions